Literature DB >> 2540005

Double-blind randomized trial of ACTH versus dexamethasone versus methylprednisolone in multiple sclerosis bouts. Clinical, cerebrospinal fluid and neurophysiological results.

C Milanese1, L La Mantia, A Salmaggi, A Campi, M Eoli, V Scaioli, A Nespolo, F Corridori.   

Abstract

30 patients with acute exacerbations of multiple sclerosis were treated by ACTH, dexamethasone or methylprednisolone in a double-blind randomized study. Clinical parameters were assessed; cerebrospinal fluid and neurophysiological parameters (visual- and brainstem-evoked potentials) were evaluated at the beginning and at the end of treatment. Dexamethasone was more effective than ACTH and 6-methylprednisolone in shortening bout duration. Neither CSF nor neurophysiological parameters were significantly affected by therapy.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2540005     DOI: 10.1159/000116368

Source DB:  PubMed          Journal:  Eur Neurol        ISSN: 0014-3022            Impact factor:   1.710


  8 in total

1.  Assessing relapses and response to relapse treatment in patients with multiple sclerosis: a nursing perspective.

Authors:  Amy Perrin Ross; June Halper; Colleen J Harris
Journal:  Int J MS Care       Date:  2012

2.  Short-term neurophysiological monitoring in multiple sclerosis bouts. Evaluation of steroid treatment.

Authors:  V Scaioli; C Milanese; A Salmaggi; L LaMantia; A Campi; M Eoli; F Panzica
Journal:  Ital J Neurol Sci       Date:  1992-03

Review 3.  Treatment of acute relapses in multiple sclerosis.

Authors:  Regina Berkovich
Journal:  Neurotherapeutics       Date:  2013-01       Impact factor: 7.620

4.  Serial evoked potentials in multiple sclerosis bouts. Relation to steroid treatment.

Authors:  L La Mantia; F Riti; C Milanese; A Salmaggi; M Eoli; C Ciano; G Avanzini
Journal:  Ital J Neurol Sci       Date:  1994-10

5.  Acute and long-term effects of adrenocorticotropin and dexamethasone on the auditory brainstem response in multiple sclerosis patients.

Authors:  J Born; B Schwab; R Schwab; H Schreiber
Journal:  J Neurol       Date:  1993-12       Impact factor: 4.849

6.  Quantitative benefit-risk assessment of methylprednisolone in multiple sclerosis relapses.

Authors:  Ola Caster; I Ralph Edwards
Journal:  BMC Neurol       Date:  2015-10-16       Impact factor: 2.474

Review 7.  Melanocortins, Melanocortin Receptors and Multiple Sclerosis.

Authors:  Robert P Lisak; Joyce A Benjamins
Journal:  Brain Sci       Date:  2017-08-14

8.  Treatment Effectiveness for Resolution of Multiple Sclerosis Relapse in a US Health Plan Population.

Authors:  Tara Nazareth; Manasi Datar; Tzy-Chyi Yu
Journal:  Neurol Ther       Date:  2019-09-28
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.